Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP108 (exenatide)
- Development stage
- Preclinical
- Lead developer
- Consegna Pharma
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
CP108 is a long-acting injectable formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, currently in preclinical development by Consegna Pharma for the treatment of type 2 diabetes. The drug utilizes a proprietary delivery technology designed to provide a 14-day sustained release of the active ingredient, aiming to reduce dosing frequency and improve patient adherence compared to existing formulations. As a GLP-1 receptor agonist, exenatide mimics the action of endogenous incretin hormones, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying to maintain glycemic control.
- Other names
- Exenatide 14-dayExenatide14-dayExenatide-14-day
02
Targets
Beyond the preview
Go deeper on CP108 (exenatide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP108 (exenatide).